Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 55.55% | 72.31% | 78.45% | 71.09% | 60.32% |
| Total Depreciation and Amortization | -56.44% | -58.88% | 30.88% | 163.89% | 50.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.21% | -56.02% | -94.81% | -94.45% | -94.37% |
| Change in Net Operating Assets | 179.75% | -148.19% | -169.16% | -165.41% | -140.87% |
| Cash from Operations | 64.77% | 67.01% | 57.39% | 36.03% | 26.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -66.11% | -374.44% | -- | -- | -- |
| Issuance of Common Stock | -78.26% | -78.26% | -98.74% | 177.38% | 238.67% |
| Repurchase of Common Stock | -- | 100.00% | -17.15% | -17.15% | -17.15% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -84.04% | -85.35% | -108.39% | 163.77% | 234.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.17% | 53.50% | 25.54% | 67.15% | 63.72% |